166 related articles for article (PubMed ID: 27943100)
1. K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.
Dalpa E; Gourvas V; Soulitzis N; Spandidos DA
Med Oncol; 2017 Jan; 34(1):6. PubMed ID: 27943100
[TBL] [Abstract][Full Text] [Related]
2. Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.
Sahu DK; Singh N; Das M; Rawat J; Gupta DK
Pediatr Surg Int; 2022 Nov; 38(11):1601-1617. PubMed ID: 36107237
[TBL] [Abstract][Full Text] [Related]
3. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Nastasă C; Tamaian R; Oniga O; Tiperciuc B
Medicina (Kaunas); 2019 Mar; 55(4):. PubMed ID: 30935124
[No Abstract] [Full Text] [Related]
4. A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.
Yi Y; Polosukhina D; Love HD; Hembd A; Pickup M; Moses HL; Lovvorn HN; Zent R; Clark PE
J Urol; 2015 Dec; 194(6):1762-70. PubMed ID: 25934441
[TBL] [Abstract][Full Text] [Related]
5. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
[TBL] [Abstract][Full Text] [Related]
6. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
[TBL] [Abstract][Full Text] [Related]
8. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
9. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
10. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
11. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
12. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
13. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
Banys-Paluchowski M; Milde-Langosch K; Fehm T; Witzel I; Oliveira-Ferrer L; Schmalfeldt B; Müller V
Breast Cancer Res Treat; 2020 Jan; 179(2):403-414. PubMed ID: 31646390
[TBL] [Abstract][Full Text] [Related]
15. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
Jeantet M; Tougeron D; Tachon G; Cortes U; Archambaut C; Fromont G; Karayan-Tapon L
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916952
[TBL] [Abstract][Full Text] [Related]
16. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
Kumar S; Hand PH; Marsden HB; Kumar P; Thor A
Anticancer Res; 1991; 11(4):1657-62. PubMed ID: 1660693
[TBL] [Abstract][Full Text] [Related]
18. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
Gailey MP; Stence AA; Jensen CS; Ma D
Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
[TBL] [Abstract][Full Text] [Related]
19. Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer.
Nagasu S; Sudo T; Kinugasa T; Yomoda T; Fujiyoshi K; Shigaki T; Akagi Y
Oncol Rep; 2019 May; 41(5):2889-2896. PubMed ID: 30864697
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma.
Howitt BE; Jia Y; Sholl LM; Barletta JA
Thyroid; 2013 Oct; 23(10):1256-62. PubMed ID: 23477374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]